TRT Before and After: What to Realistically Expect

If you are researching testosterone before and after outcomes, the realistic expectation is a gradual, individually variable set of changes rather than an overnight transformation. In a widely cited systematic review of the time-course of testosterone effects in hypogonadal men (Saad et al., European Journal of Endocrinology, 2011), different symptoms responded on different schedules: sexual interest tended to shift within weeks, while changes in body composition and bone took many months. Crucially, these are general literature ranges with wide individual variation, no guarantees, and outcomes are determined by your prescribing clinician.

What does a realistic TRT timeline look like?

The single most useful map of “before and after” comes from the Saad 2011 systematic review, which pooled published studies to estimate when each effect tends to begin and when it tends to plateau in hypogonadal men. The table below summarizes those general ranges. Read it as a guide to sequence and patience, not as a prediction of what any one person will feel.

Effect (hypogonadal men)	Onset (general range)	Maximum / plateau (general range)
Libido, sexual desire, fantasies	~3 weeks (about 30 days)	Plateau ~6 weeks
Erections and ejaculations	Slower than libido	Up to 6 months
Quality of life (e.g., AMS scores)	~3-4 weeks	Onset ~3-4 weeks; maximum benefits take longer (timeframe not specified)
Depressive mood	3-6 weeks	Maximum ~18-30 weeks
Fat mass, lean mass, muscle strength	~12-16 weeks	Stabilize 6-12 months; marginal gains over years
Hematocrit / hemoglobin (erythropoiesis)	Apparent ~3 months	Maximum ~9-12 months
PSA	Rises only marginally	Plateaus around 12 months; further rise attributed to aging, not therapy
Bone mineral density	Detectable ~6 months	Continues for at least 3 years

All figures above are drawn from the Saad et al. 2011 systematic review of hypogonadal men. They describe the literature, not a contract. For a deeper look at the early phase, see our companion piece on how long TRT takes to work.

How big are the changes, really?

Sequence is one thing; magnitude is another. Here the evidence counsels humility. In the Testosterone Trials (Snyder et al., NEJM 2016) — 790 men aged 65 and older with total testosterone below 275 ng/dL, treated for one year — testosterone significantly improved sexual activity, sexual desire, and erectile function versus placebo, with only moderate effects on mood and modest effects on physical function. Across all T-Trials participants combined, the share with a meaningful improvement (at least 50 m) in 6-minute walk distance was 20.5% on testosterone versus 12.6% on placebo; however, in the dedicated Physical Function Trial this primary 6-minute-walk endpoint was not statistically significant. That walking figure also belongs only to those men aged 65+; it should not be generalized to younger men.

A systematic review and meta-analysis published alongside the Endocrine Society guideline (JCEM 2018) reached a similar conclusion: testosterone produced small but statistically significant improvements in sexual desire, erectile function, and sexual satisfaction, while pooled analyses found no statistically significant effect on energy or mood. So if your “before and after” hopes center on libido and sexual function, the evidence is most supportive there; if they center on mood or energy, the pooled data are uncertain. Individual results vary.

Who qualifies, and how is the diagnosis made?

TRT is not a wellness add-on you can simply choose. Testosterone is a DEA Schedule III controlled substance under the Anabolic Steroids Control Act of 1990, which means a valid prescription and a documented diagnosis are required. Both major guidelines require consistent symptoms plus two low early-morning testosterone measurements before a diagnosis is made.

The exact threshold differs by guideline, assay, and reference range, and is provider-determined. The American Urological Association (2018) uses a total testosterone below 300 ng/dL as a reasonable cut-off, while the Endocrine Society (2018) cites a harmonized lower limit of normal of 264 ng/dL in healthy nonobese young men. These are not interchangeable universal numbers. If you are weighing options, our overview of signs you may need hormone replacement therapy and the comparison of enclomiphene versus TRT may help frame the conversation with a clinician.

What monitoring does TRT require before and after starting?

The “after” in TRT includes lab work, not just how you feel. Monitoring is mandatory, because testosterone has measurable effects on the blood, the prostate, and blood pressure.

Hematocrit. Testosterone stimulates red blood cell production; in the Saad review, the rise in hematocrit became apparent around 3 months and peaked at roughly 9-12 months. The Endocrine Society 2010 guideline recommends measuring hematocrit at baseline, at 3-6 months, and annually thereafter; therapy should be held if hematocrit exceeds 54% until it falls to a safe level, and a baseline above 50% is a relative contraindication.

PSA and prostate. In the Saad review, PSA rose only marginally and plateaued around 12 months, with further increases attributed to aging rather than therapy. The Endocrine Society 2018 guideline advises urological consultation if, within the first 12 months, there is a confirmed PSA increase greater than 1.4 ng/mL above baseline, a confirmed PSA above 4.0 ng/mL, or a prostatic abnormality on exam.

Blood pressure. On February 28, 2025, the FDA issued class-wide labeling changes for testosterone products after ambulatory blood-pressure monitoring confirmed a blood-pressure increase across the class; a blood-pressure warning was added to products that lacked one. The same action added TRAVERSE results, retained the age-related-hypogonadism Limitation of Use, and removed prior boxed-warning language on cardiovascular outcomes.

Is TRT cardiovascularly safe?

The largest dedicated safety trial, TRAVERSE (Lincoff et al., NEJM 2023), enrolled 5,246 men aged 45-80 with hypogonadism and preexisting or high risk of cardiovascular disease. Testosterone was noninferior to placebo for major adverse cardiac events (182 events, 7.0%, vs 190, 7.3%; hazard ratio 0.96, 95% CI 0.78-1.17). However, the testosterone group had higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism. Noninferiority for major cardiac events is not the same as “cardiovascularly safe,” and those findings apply to that specific higher-risk population.

Does the FDA approve testosterone for “low T”?

FDA-approved testosterone products exist, but their indication is for classic (primary or secondary) hypogonadism due to specific medical conditions. The agency has concluded the evidence does not support an indication for age-related “low testosterone,” and in 2015 it cautioned against this use and required labeling changes (Nguyen et al., NEJM Perspective 2015); that Limitation of Use was retained in the 2025 labeling update. We do not assert the FDA-approval status of any specific product offered through Revive. Some TRT-adjunct options discussed elsewhere — such as hCG with TRT — may be compounded; compounded products are not FDA-approved, and the FDA has not evaluated them for safety, quality, or efficacy.

Frequently asked questions

How soon will I notice TRT working?

In the Saad et al. 2011 systematic review of hypogonadal men, libido and sexual desire tended to improve from around 3 weeks and plateau near 6 weeks, while erections could take up to 6 months and body composition changes unfolded from roughly 12-16 weeks onward. These are general literature ranges with wide individual variation, not guarantees. Your actual timeline is determined by your clinician and your individual response.

How dramatic are the “before and after” results?

Pooled randomized trials suggest the magnitude is modest. The JCEM 2018 meta-analysis found small but significant improvements in sexual desire, erectile function, and satisfaction, with no statistically significant pooled effect on energy or mood. The T-Trials (men 65+) showed moderate sexual benefits and only modest physical effects. Expect gradual change rather than transformation, and remember individual results vary.

What lab monitoring does TRT require?

Per Endocrine Society guidance, hematocrit is checked at baseline, 3-6 months, and annually, with therapy held if it exceeds 54%. PSA and prostate are monitored, with urology referral triggered by a confirmed PSA rise greater than 1.4 ng/mL above baseline, a confirmed PSA above 4.0 ng/mL, or an abnormal exam in the first 12 months. The FDA also added a class-wide blood-pressure warning in 2025, so blood pressure is monitored too.

Is testosterone a controlled substance?

Yes. Testosterone is a DEA Schedule III controlled substance under the Anabolic Steroids Control Act of 1990. It requires a valid prescription, a documented diagnosis (consistent symptoms plus two low early-morning testosterone tests), and ongoing monitoring. It cannot be obtained or used without clinician oversight.

What testosterone level is considered “low”?

Thresholds vary by guideline, assay, and reference range and are provider-determined. The AUA uses a total testosterone below 300 ng/dL, while the Endocrine Society cites a lower limit of normal of 264 ng/dL in healthy nonobese young men. Either way, diagnosis requires two confirmatory early-morning measurements combined with consistent symptoms, not a single number alone.

Is TRT safe for the heart?

In TRAVERSE (men 45-80 at elevated cardiovascular risk), testosterone was noninferior to placebo for major adverse cardiac events, but the testosterone group had higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism. Noninferiority is not a guarantee of safety, and these findings reflect that specific higher-risk population. Discuss your own risk profile with a licensed provider.